ymjЯкутский медицинский журналYakut Medical Journal1813-19052312-1017ЯНЦ КМП10.25789/YMJ.2025.89.25ymj-439Research ArticleТОЧКА ЗРЕНИЯPOINT OF VIEWЖировая болезнь печени как фактор риска нарушения гемостаза у пациентов с COVID-19Fatty liver disease as a risk factor for impaired hemostasis in patients with COVID-19ТириковаО. В.TirikovaO. V.

Тирикова Олеся Владимировна – ассистент кафедры

ORCID: 0009-0001-7381-4084 

664003, г. Иркутск, ул. Красного Восстания, 1

otirikova@mail.ruhttps://orcid.org/0009-0002-3255-8159СудьяроваД. В.SudyarovaD. V.

Судьярова Диана Викторовна – студентка 6 курса

664003, г. Иркутск, ул. Красного Восстания, 1

d.sudyarova@yandex.ruhttps://orcid.org/0009-0008-5283-613XЭльмуродоваН. Б.ElmurodovaN. B.

Эльмуродова Нодира Баходуровна – студентка 6 курса

664003, г. Иркутск, ул. Красного Восстания, 1

nodira.elmurodova@inbox.ruФГБОУ ВО «Иркутский государственный медицинский университет»Россия20252103202501111114Copyright © Тирикова О.В., Судьярова Д.В., Эльмуродова Н.Б., 20252025Тирикова О.В., Судьярова Д.В., Эльмуродова Н.Б.Tirikova O.V., Sudyarova D.V., Elmurodova N.B.This work is licensed under a Creative Commons Attribution 4.0 License.https://ymj.elpub.ru/jour/article/view/439

Изучено влияние жировой болезни печени (ЖБП) на нарушения гемостаза при COVID-19. У 30%  умерших от COVID-19 были выявлены нарушения  гемостаза. ЖБП чаще всего встречалась (19%) у  умерших от COVID-19 и имевших нарушение  гемостаза, чем у умерших от COVID-19 без  нарушения гемостаза (12%) р = 0,019. Таким  образом, результаты исследования показали статистическую значимость патологии системы гемостаза в структуре смертности от COVID-19. 

The effect of fatty liver disease (FLD) on hemostasis disorders in COVID-19 was studied. Hemostasis disorders were detected in 30% of COVID-19 deaths. FLD was more common (19%) in COVID-19 deaths with hemostasis disorders than in COVID-19 deaths without hemostasis disorders (12%), p = 0.019. Thus, the study results showed statistical significance of hemostasis pathology in the COVID-19 mortality structure. 

жировая болезнь печени (ЖБП)тромбоэмболия легочной артерии (ТЭЛА)COVID-19нарушение гемостазатромбозfatty liver disease (FLD)pulmonary embolism (PE)COVID-19hemostasis disorderthrombosisReferencesИвашкин В.Т. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации // Рос. журн. гастроэнтерол. гепатол. колопроктол. 2016. Т. 26, №2. C. 24 – 42.Ivashkin V.T., Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for Liver Research and the Russian Gastroenterological Association // Russian Journal of Gastroenterology. Hepatol. Coloproctol. 2016. Vol. 26. No. 2. P. 24 – 42.Эндотелиальная дисфункция у пациентов с неалкогольной жировой болезнью печени / О.В. Тирикова, Н.М. Козлова, С.М. Елисеев [и др.] // Экспериментальная и клиническая гастроэнтерология. 2022;203(7): 45-53. DOI: 10.31146/1682-8658-ЭКГ-203-7-45-53Tirikova O.V., Kozlova N.M., Eliseev et al. Endothelial dysfunction in patients with non-alcoholic fatty liver disease. Experimental and clinical gastroenterology. 2022;203(7): 45–53. DOI: 10.31146/1682-8658-ecg-203-7-45-53Тирикова О.В. Клинико-морфологические аспекты неалкогольной жировой болезни печени и её ассоциация с сердечно-сосудистой патологией: Дис. … к.м.н..78 с.Tirikova O.V., Dissertation for the degree of Candidate of Medical Sciences: Clinical and morphological aspects of non-alcoholic fatty liver disease and its association with cardiovascular pathology. Diss. … cand. med. sciences p.78A new definition of metabolically associated fatty liver disease: a consensus statement by international experts / M. Eslam [et al.] // Journal of Hepatology. 2020. Volume 73. Number 1. Р. 202-209.A new definition of metabolically associated fatty liver disease: a consensus statement by international experts / M. Eslam [et al.] // Journal of Hepatology. 2020. Volume 73. Number 1. Р. 202-209.Brunt E.M. Pathology of fatty liver disease // Modern Pathology. 2007. Vol. 20. N. 40. Р. 48.Brunt E.M. Pathology of fatty liver disease // Modern Pathology. 2007. Vol. 20. N. 40. Р. 48.Carme Font. Thrombosis, cancer, and COVID-19 / Norman Brito-Dellan., Nikolaos Tsoukalas // Support Care Cancer. 2022; 30(10): 8491–8500.Carme Font. Thrombosis, cancer, and COVID-19 / Norman Brito-Dellan., Nikolaos Tsoukalas // Support Care Cancer. 2022; 30(10): 8491–8500.COVID-19 and its control: mechanical and clinical studies / T. Marzha, G.J. Webb, A.S. Barrett [et al.] // The State Environmental Protection Inspectorate. May 2021;18(5):348-364. doi: 10.1038/s41575-021-00426-4.COVID-19 and its control: mechanical and clinical studies / T. Marzha, G.J. Webb, A.S. Barrett [et al.] // The State Environmental Protection Inspectorate. May 2021;18(5):348-364. doi: 10.1038/s41575-021-00426-4.Endothelial dysfunction and peroxynitrite formation are early events in angiotensin – induced cardiovascular disorders / Wattanpitayakul S.K. [et al.] // FASEB J. 2000;14(2):271–278. doi:10.1096/fasebj.14.2.271.Endothelial dysfunction and peroxynitrite formation are early events in angiotensin – induced cardiovascular disorders / Wattanpitayakul S.K. [et al.] // FASEB J. 2000;14(2):271–278. doi: 10.1096/fasebj.14.2.271.Increased activity of blood coagulation factors VIII, IX, XI and XII in non-alcoholic fatty liver disease / A. Kotronen, L. Yutsi-Korhonen, K. Sevastyanova [et al.] // Liver, February 2011;31(2):176-83. doi: 10.1111/j.1478-3231.2010.02375. x.Increased activity of blood coagulation factors VIII, IX, XI and XII in non-alcoholic fatty liver disease / A. Kotronen, L. Yutsi-Korhonen, K. Sevastyanova [et al.] // Liver, February 2011;31(2):176-83. doi: 10.1111/j.1478-3231.2010.02375. x.Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter / Stefan Kiriak, Carol Stanciu [et al.] // Gastroenterol Hepatol. 2021; 2021: 6696857.Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter / Stefan Kiriak, Carol Stanciu [et al.] // Gastroenterol Hepatol. 2021; 2021: 6696857.Nonalcoholic fatty liver disease 2020: the state of the disease / Thomas G. Cotter., Mary Rinella // Gastroenterology. 2020.158.7. Р. 1851-1864.Nonalcoholic fatty liver disease 2020: the state of the disease / Thomas G. Cotter., Mary Rinella // Gastroenterology. 2020.158.7. Р. 1851-1864.Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways / Ding YQ, He L, Zhang QL [et al.] // J Pathol. 2004;203(2):622-630.Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways / Ding YQ, He L, Zhang QL [et al.] // J Pathol. 2004;203(2):622-630.Ong J.P., Pitts A., Younossi Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease // Journal of Hepatology. 2008. Vol. 49. N 4. P. 608 612. DOI: 10.1016/j.jhep.2008.06.018.Ong J.P., Pitts A., Younossi Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease // Journal of Hepatology. 2008. Vol. 49. N 4. P. 608 612. DOI: 10.1016/j.jhep.2008.06.018.Pathophysiology of COVID-19: the critical role of hemostasis / de Andrade, S.A., de Souza, D.A., Torres, A.L. [et al.] // Microbiol infects the anterior cell. 2022, June 3;12:896972. doi: 10.3389/fcimb.2022.896972.Pathophysiology of COVID-19: the critical role of hemostasis / de Andrade, S.A., de Souza, D.A., Torres, A.L. [et al.] // Microbiol infects the anterior cell. 2022, June 3;12:896972. doi: 10.3389/fcimb.2022.896972.Thrombosis in COVID-19 / Hanff TC. et al. // Am J Hematol. 2020; 95 :1578–1589.Thrombosis in COVID-19 / Hanff TC. et al. // Am J Hematol. 2020; 95 :1578–1589.Тohandas S, Vairappan B. Severe acute respiratory syndrome coronavirus-2 infection and the gut–liver axis. J Dig Dis. 2020; 21:687–695.Тohandas S, Vairappan B. Severe acute respiratory syndrome coronavirus-2 infection and the gut–liver axis. J Dig Dis. 2020; 21:687–695.

The authors declare that there are no conflicts of interest present.